Elo Mutual Pension Insurance trimmed its stake in Vertex Pharmaceuticals by 4% in Q4, now holding $9.49 million in shares. Several other institutional investors also made notable adjustments, with ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Major indices turned in a mixed performance on Monday as market participants patiently awaited clarity on Donald Trump's ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.60% to $484.82 Monday, on what proved to be an all-around favorable ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Marks, a well-respected hematologist oncologist who has been at the agency since 2012, said in his resignation letter his ...

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Vertex Pharmaceuticals (VRTX) is the second stock to buy for the Nasdaq 100 correction. The biotech stock offers stability ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look ...